Paolo Ghia

Paolo Ghia, a leading expert in chronic lymphocytic leukemia (CLL) from Vita-Salute San Raffaele University, joins forces with Arnon Kater from the University of Amsterdam to discuss the latest ESMO clinical practice guidelines. They dive into innovative treatment strategies for relapsed CLL, including the use of the non-covalent BTK inhibitor pirtobrutinib and the promising roles of allogeneic stem cell transplantation and CAR T-cell therapy. The conversation also highlights the evolving landscape of therapies like BTK degraders and bispecific antibodies.

Dr. Jennifer R Brown, a leader in CLL research at Dana-Farber, and Prof. Paolo Ghia from Milan, dive into the latest breakthroughs in chronic lymphocytic leukemia. They explore the role of new therapies like BTK inhibitors, comparing their effectiveness with traditional treatments. The conversation highlights the significance of monitoring minimal residual disease and discusses recent findings on treatment risks like hypertension. They also touch on innovative strategies emerged during the COVID-19 pandemic, paving the way for future advancements in CLL care.

Experts Stephen Ansell, Paolo Ghia, and Andrew Rawstron discuss Monoclonal B-cell lymphocytosis (MBL) as a precursor to CLL, exploring biology, classification, and early interception possibilities. They cover MBL progression, genetic similarities with CLL, B-cell receptor as an early marker, and the importance of immune system interactions for early intervention.